Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06751238 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
A Phase 1 study of Juvenile Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 7
- Study locations
NCT06751238: Recruiting Phase 1 study of Juvenile Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals.
NCT06751238 is a Phase 1 study of Juvenile Psoriatic Arthritis that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06751238, a Phase 1 study of Juvenile Psoriatic Arthritis, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
Primary Outcome
Maximum concentration of secukinumab on Day 1
Conditions Studied
Interventions
- BIOLOGICAL Secukinumab
Study Locations (7)
Ohio
- Cincinnati Childrens Hospital - Cincinnati
- Univ Hosp Cleveland Medical Center - Cleveland
Florida
- University of Florida - Gainesville
Illinois
- Ann and Robert H Lurie Childs Hosp - Chicago
North Carolina
- Levine Childrens Hospital - Charlotte
Oregon
- Legacy Emanuel Research Hosp Portland - Portland
Texas
- Texas Arthritis Center - El Paso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-09-24 |
| Est. Completion | 2032-12-01 |
| Phase | Phase 1 |
What NCT06751238 shows while recruiting
NCT06751238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Juvenile Psoriatic Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Secukinumab is the first listed.
NCT06751238 lists 7 locations in 6 states (Ohio, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT06751238 about?
NCT06751238 is a clinical study titled "Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).". The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
What is the current status of trial NCT06751238?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-09-24. Estimated completion is 2032-12-01.
What conditions does trial NCT06751238 study?
This clinical trial studies the following conditions: Juvenile Psoriatic Arthritis.
What interventions are being tested in trial NCT06751238?
The interventions under investigation include: Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06751238?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06751238 being conducted?
This trial has 7 study locations across Florida, Illinois, North Carolina, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06751238's enrollment target sits among peer trials
20 1630th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI